Cochrane · systematic review · CD012065
Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review
Nevitt, SJ, Sudell, M, Tudur Smith, C, et al. · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
9
current version
GRADE rated
9
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 1 · 11.1%Moderate 4 · 44.4%High 4 · 44.4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 2 versionsTopiramate compared with carbamazepine for epilepsy (time to treatment failure)
Population: adults and children with newly onset focal or generalised epilepsy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Time to treatment failure (any reason related to treatment) All participants ‐ adjusted by seizure type Range of Topiramate vs carbamazepine | HR 1.16 [0.97, 1.38] | 2 studies · 1129 participants | Moderate Downgraded: risk of bias |
Time to treatment failure (any reason related to treatment)Subgroup: focal onset seizures Range of Topiramate vs carbamazepine | HR 1.21 [1.01, 1.46] | 2 studies · 937 participants | Moderate Downgraded: risk of bias |
Time to treatment failure (any reason related to treatment) Subgroup: generalised onset tonic‐clonic seizures or unclassified epilepsy Range of Topiramate vs carbamazepine | HR 0.88 [0.56, 1.39] | 2 studies · 192 participants | Low Downgraded: imprecision, indirectness |
Topiramate compared with carbamazepine for epilepsy (secondary outcomes)
Population: adults and children with newly onset focal or generalised epilepsy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Time to first seizure after randomisation All participants Range of Topiramate vs carbamazepine | HR 1.11 [0.96, 1.29] | 2 studies · 1115 participants | High |
Time to first seizure after randomisation Subgroup: focal onset seizures Range of Topiramate vs carbamazepine | HR 1.12 [0.95, 1.31] | 2 studies · 925 participants | High |
Time to first seizure after randomisation Subgroup: generalised onset tonic‐clonic seizures or unclassified epilepsy Range of Topiramate vs carbamazepine | HR 1.08 [0.7, 1.66] | 2 studies · 190 participants | Moderate Downgraded: imprecision, indirectness |
Time to 12‐month remission of seizures All participants Range of Topiramate vs carbamazepine | HR 0.84 [0.71, 0.99] | 2 studies · 1115 participants | High |
Time to 12‐month remission of seizures Subgroup: focal onset seizures Range of Topiramate vs carbamazepine | HR 0.82 [0.69, 0.99] | 2 studies · 925 participants | High |
Time to 12‐month remission of seizures Subgroup: generalised onset tonic‐clonic seizures or unclassified epilepsy Range of Topiramate vs carbamazepine | HR 0.92 [0.61, 1.41] | 2 studies · 190 participants | Moderate Downgraded: imprecision, indirectness |